Patents Assigned to Institut Pasteur
  • Patent number: 11981750
    Abstract: The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: May 14, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVIRONNEMENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: John P. Bannantine, Gilles Etienne, Sylvie Bay, Franck Biet
  • Patent number: 11976305
    Abstract: The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 7, 2024
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Mathieu Mateo, Sylvain Baize, Frédéric Tangy
  • Patent number: 11969467
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Patent number: 11964013
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: September 12, 2023
    Date of Patent: April 23, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Patent number: 11946056
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: April 2, 2024
    Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEUR
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Publication number: 20240100048
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Application
    Filed: December 7, 2023
    Publication date: March 28, 2024
    Applicants: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa BARREIRA DA SILVA, Matthew ALBERT
  • Patent number: 11938199
    Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 26, 2024
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Yves-Louis Janin, Eloi Paul Coutant, Vincent Hervin, Glwadys Gagnot, Yves Jacob, Sophie Goyard, Thierry Rose
  • Patent number: 11926648
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: March 12, 2024
    Assignees: INSTITUT PASTEUR, IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Patent number: 11918613
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: March 5, 2024
    Assignees: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • Patent number: 11911462
    Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: February 27, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
  • Patent number: 11905516
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 20, 2024
    Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEUR
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Patent number: 11884708
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: January 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Patent number: 11883398
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: January 30, 2024
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11872276
    Abstract: The present invention is directed to a Zika virus (ZIKV) chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition. The present invention provides means, in particular polynucleotides, vectors and cells expressing said chimeric polyepitope. The present invention also relates to a composition or a vaccine comprising at least one of said polyepitope, polynucleotide, vector or host cell for use in the prevention of a ZIKV infection in a human subject, or for use in the prevention of ZIKV and dengue virus (DENV) infections in a human subject.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: January 16, 2024
    Assignees: INSTITUT PASTEUR, UNIVERSIDAD EL BOSQUE
    Inventors: Claude Roth, Etienne Simon-Loriere, Anavaj Sakuntabhai, Felix Delgado
  • Patent number: 11857616
    Abstract: The present invention relates to recombinant measles virus expressing Zika virus proteins and their applications, in particular in inducing preventive protection against Zika virus. The present invention is directed to recombinant measles virus (MV) expressing at least (i) the precursor of membrane (prM) protein of a Zika virus (ZIKV), and the envelope (E) protein of a ZIKV or a truncated version thereof, or (ii) the E protein of a ZIKV or a truncated version thereof, and concerns recombinant infectious particles of said MV-ZIKV able to replicate in a host after an administration, and also Virus Like Particles (VLPs) that contain these ZIKV proteins at their surface. The present invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles and VLPs.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: January 2, 2024
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Etienne Simon-Loriere
  • Publication number: 20230392217
    Abstract: The present invention relates to a composition for diagnosing the susceptibility of Staphylococcus aureus to antibiotics, and a use thereof. Particularly, it has been ascertained that sosA is a marker specific to Staphylococcus aureus, and that the expression level of sosA is exhibited similarly to antibiotic susceptibility/resistance properties so as to be usable as a means for diagnosing the susceptibility/resistance of Staphylococcus aureus to antibiotics, and the present invention diagnoses the susceptibility/resistance of Staphylococcus aureus present in samples to antibiotics by using antibodies specifically binding to protein SosA, and thus provides, as a means for diagnosing the susceptibility of Staphylococcus aureus to antibiotics, a composition containing an agent for measuring the mRNA expression level of the sosA gene or an agent for measuring the expression level of the SosA protein.
    Type: Application
    Filed: October 15, 2021
    Publication date: December 7, 2023
    Applicant: INSTITUT PASTEUR KOREA
    Inventors: Soojin JANG, Yunmi LEE
  • Patent number: 11834468
    Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 5, 2023
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurence Mulard, Guillaume Le Heiget, Zhaohu Hu, Louis-Antoine Barel, Isabelle Andre, Claire Moulis, Magali Remaud-Simeon, Sophie Barbe, Mounir Benkoulouche, Akli Ben Imeddourene
  • Publication number: 20230364232
    Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
  • Patent number: 11815513
    Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 14, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvie Van Der Werf, Nicolas Escriou, Caroline Demeret, Stéphane Petres, Pierre Lafaye, Jacques Bellalou
  • Publication number: 20230346728
    Abstract: A method of treating obesity, preventing weight gain, reducing the rate of weight gain, and treating adverse effects related to obesity by administering SANA to induce thermogenesis in a subject.
    Type: Application
    Filed: March 29, 2023
    Publication date: November 2, 2023
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Gérman Adrian Galliussi López, Mária Pia Garat Nuñez